ArticleTechnology in cancer research & treatment
CAMSAP3 Suppresses Breast Cancer Metastasis and Serves as an Independent Prognostic Marker.
Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionBreast cancer metastasis remains the leading cause of disease-related mortality. While calmodulin-regulated spectrin-associated protein 3 (CAMSAP3) has been implicated as a metastasis suppressor in other cancers, its role in breast cancer remains poorly defined. This study aimed to investigate the prognostic significance and functional impact of CAMSAP3 in breast cancer.MethodsCAMSAP3 protein expression was evaluated by immunohistochemistry in 137 primary breast cancer specimens and correlated with clinicopathological features and survival outcomes. Kaplan-Meier and Cox regression analyses were performed to assess distant relapse-free survival (DRFS). Functional assays, including wound healing and Transwell invasion assays, were conducted in MDA-MB-231 and HCC1937 cells following CAMSAP3 overexpression or knockdown. External mRNA-level validation was performed using the Kaplan-Meier Plotter database.ResultsHigh CAMSAP3 expression was significantly associated with favorable features, including lower histological grade, hormone receptor positivity, reduced proliferation index, and fewer triple-negative phenotypes. Patients with high CAMSAP3 expression exhibited significantly improved DRFS, which was independently validated using a public mRNA dataset showing improved distant metastasis-free survival (DMFS). In vitro, CAMSAP3 overexpression inhibited migration and invasion of MDA-MB-231 cells, while CAMSAP3 knockdown enhanced these phenotypes in HCC1937 cells.ConclusionCAMSAP3 is a potential metastasis suppressor and independent prognostic marker in breast cancer. Its high expression is associated with less aggressive tumor characteristics and improved survival, possibly through inhibition of cancer cell migration and invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.